Last Chance for WIMPs: Physicists Launch All-Out Hunt for Dark-Matter Candidate

Physicists are hatching a plan to give a popular but elusive dark-matter candidate a last chance to reveal itself. For decades, physicists have hypothesized that weakly interacting massive particles (WIMPs) are the strongest candidate for dark matter — the mysterious substance that makes up 85% of the Universe’s mass. But several experiments have failed to find evidence for WIMPs, meaning that, if they exist, their properties are unlike those originally predicted. Now, researchers are pushing to build a final generation of supersensitive detectors — or one ‘ultimate’ detector — that will leave the particles no place to hide.

“The WIMP hypothesis will face its real reckoning after these next-generation detectors run,” says Mariangela Lisanti, a physicist at Princeton University in New Jersey.

Physicists have long predicted that an invisible substance, which has mass but doesn’t interact with light, permeates the Universe. The gravitational effects of dark matter would explain why

Read More
Read More

In the vice presidential debate, only one candidate looked into the camera and spoke to ‘you’

Because television is a visual medium, what is seen often registers more vividly than what is said. From prestige dramas to reality-show schlock, TV relies on character contrasts, the sharper the better. Much the same is true of politics, whose practitioners like to speak of the importance of “optics.”

Wednesday night’s vice presidential debate between Mike Pence and Kamala Harris was a study in contrasts that went well beyond their parties and positions. It may not have been riveting television, but it was revealing television.

The most significant difference, of course, was built into the evening from the start. History was made by the simple act of Harris, the first woman of color on a major-party ticket, sharing a stage (from a distance of 12 feet) with Pence. Another welcome, impossible-to-miss distinction was the evening’s civility compared with last week’s demolition derby masquerading as a presidential debate, which featured President

Read More
Read More

Scientists find evidence of exotic state of matter in candidate material for quantum computers

Scientists find evidence of exotic state of matter in candidate material for quantum computers
An illustration of the crystal structure of ruthenium trichloride showing the simple honeycomb lattice of ruthenium ions and chlorine ions. The twisted octahedra formed by chlorine around the electron spin of each ruthenium atom are mirror images of each other. This twist is key to the compound’s unusual behavior, which is evidence that it may contain an example of a quantum spin liquid. Credit: Courtesy of Arkady Shekhter/ National High Magnetic Field Laboratory

Using a novel technique, scientists working at the Florida State University-headquartered National High Magnetic Field Laboratory have found evidence for a quantum spin liquid, a state of matter that is promising as a building block for the quantum computers of tomorrow.


Researchers discovered the exciting behavior while studying the so-called electron spins in the compound ruthenium trichloride. Their findings, published today in the journal Nature Physics , show that electron spins interact across the material, effectively lowering

Read More
Read More

TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate

  •  Initiating clinical trials to evaluate investigational toll-like receptor 9 agonist, SD-101, in patients with uveal melanoma liver metastases followed by three additional indications.

  • Aspiring to overcome the challenges of treating patients with solid tumors through our multi-pronged approach to stimulate the immune system and deliver immuno-oncology therapies directly to the site of the disease, with the goal of improving the therapeutic index

  • Working to redefine the treatment of hard-to-treat solid tumors in the liver or pancreas by combining TriSalus’ proprietary FDA cleared intravascular, regional drug delivery technology for liver and pancreatic infusion with investigational SD-101 and standard of care therapy

TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors, announced today its therapeutic clinical development strategy following the successful acquisition of SD-101, an investigational IND-ready immunotherapy, from Dynavax Technologies on August 3, 2020.

SD-101 is an investigational toll-like receptor 9 (TLR9) agonist

Read More
Read More